2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    PI3K/Akt/mTOR
  4. ATM/ATR

ATM/ATR

Ataxia telangiectasia mutated; ATM and RAD3 related

ATM/ATR

Related Products

PDF 0.19 MB

ATM/ATR, members of the phosphatidyl inositol 3-kinase-like family of serine/threonine protein kinases (PIKKs), are widely known as being central players in the mitotic DNA damage response (DDR), mounting responses to DNA double-strand breaks (DSBs) and single-stranded DNA (ssDNA) respectively. Activation of ATM by ionizing radiation results in the activation of signal transduction pathways that induce cell cycle arrest at G1/S, S and G2/M. ATR is required for cell cycle arrest in response to DNA-damaging agents such as ultraviolet radiation that cause bulky lesions.

Upon activation, ATM/ATR phosphorylate numerous targets to stabilize stalled replication forks, repair damaged DNA, and inhibit cell cycle progression to ensure survival of the cell and safeguard integrity of the genome. ATM and ATR are central players in activating cell cycle checkpoints and function as an active barrier against genome instability and tumorigenesis in replicating cells.

ATM/ATR Isoform Specific Products:

ATM/ATR Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144687
    ATM Inhibitor-4
    		Inhibitor
    ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability.
    ATM Inhibitor-4
  • HY-153787
    ATM Inhibitor-6
    		Inhibitor
    ATM inhibitor-6 (A-193) is a selective ATM kinase inhibitor. ATM inhibitor-6 can be used in cancer research.
    ATM Inhibitor-6
  • HY-157767
    Abd110
    		Inhibitor
    Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs.
    Abd110
  • HY-144214
    ATR-IN-10
    		Inhibitor
    ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC50 value of 2.978 μM.
    ATR-IN-10
  • HY-162002
    WSD0628
    		Inhibitor
    WSD0628 is a brain penetrant and potent ATM inhibitor with profound radiosensitizing effect.
    WSD0628
  • HY-157764
    PROTAC ATR degrader-1
    		Degrader
    PROTAC ATR degrader-1 (compound ZS-7) is a potent PROTAC degrader of ataxia telangiectasia and Rad3-related (ATR), with DC50 of 0.53 μM. PROTAC ATR degrader-1 plays an importnt role in cancer research.
    PROTAC ATR degrader-1
  • HY-147190
    ATR-IN-19
    		Inhibitor
    ATR-IN-19 (Compound 15 R-configure) is an ATR inhibitor.
    ATR-IN-19
  • HY-142931
    ATM-IN-1
    		Inhibitor
    ATM-IN-1 is a potent inhibitor of ATM. ATM is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3).
    ATM-IN-1
  • HY-147567
    ATR-IN-15
    		Inhibitor
    ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC50 of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and PI3K, with IC50 values of 47, 663 and 5131 nM, respectively.
    ATR-IN-15
  • HY-153393
    ATR-IN-21
    		Inhibitor
    ATR-IN-21 (compound 60) is a potent ATR inhibitor with an IC50 value of <1000 nM.
    ATR-IN-21
  • HY-147569
    ATR-IN-17
    		Inhibitor
    ATR-IN-17 (compound 88) is a potent ATR kinase inhibitor. ATR-IN-17 shows good anticancer activity in LoVo cells, with an IC50 of 1 nM.
    ATR-IN-17
  • HY-153400
    ATR-IN-22
    		Inhibitor
    ATR-IN-22 (Compound 34) is an orally active ATR inhibitor. ATR-IN-22 inhibits MIAPaCa-2 proliferation (IC50 <1 μM). ATR-IN-22 shows anti-tumor activity in colon cancer.
    ATR-IN-22
  • HY-150617A
    (Rac)-Lartesertib
    		Inhibitor
    (Rac)-Lartesertib ((Rac)-M4076; (Rac)-ATM Inhibitor-5) is an isoform of Lartesertib (HY-150617), which is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1).
    (Rac)-Lartesertib
  • HY-144685
    ATM Inhibitor-2
    		Inhibitor
    ATM Inhibitor-2 (compound 7) is a potent and selective ATM inhibitor, with an IC50 of <1 nM.
    ATM Inhibitor-2
  • HY-151915
    ATR-IN-20
    		Inhibitor
    ATR-IN-20 is a potent ATR (ATM/ATR) inhibitor with an IC50 of 3 nM. ATR-IN-20 possess an inhibitory effect on mTOR (IC50 of 18 nM) while displaying good selectivity against PI3Kα (100 nM), ATM (100 nM), and DNA-PK (662 nM). ATR-IN-20 exhibits excellent pharmacokinetic profile (F = 30%), and has anticancer effects.
    ATR-IN-20
  • HY-144436
    ATR-IN-12
    		Inhibitor
    ATR-IN-12 (Compound 5g) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with an IC50 value of 0.007 μM. ATR-IN-12 displays good anti-tumor activity and significantly reduces the phosphorylation level of ATR and its downstream signaling protein. ATR-IN-12 is a promising lead compound for subsequent agent discovery targeting ATR kinase.
    ATR-IN-12
  • HY-142924
    ATR-IN-8
    		Inhibitor
    ATR-IN-8 is a potent inhibitor of ATR. ATR is a key enzyme in the homologous recombination repair pathway and belongs to the PIKK family. ATR-IN-8 has the potential for the research of cancer diseases (extracted from patent WO2021143821A1, compound 3).
    ATR-IN-8
  • HY-144435
    ATR-IN-11
    		Inhibitor
    ATR-IN-11 (Compound Hit01) is a potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. ATR kinase is a key regulating protein within the DNA damage response (DDR), responsible for sensing replication stress (RS). ATR-IN-11 is a promising lead compound for subsequent agent discovery targeting ATR kinase. ATR-IN-11 has the potential for the research of cancer disease.
    ATR-IN-11
  • HY-141478
    Antitumor agent-28
    		Inhibitor
    Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity.
    Antitumor agent-28
  • HY-153729
    ATR-IN-29
    		Inhibitor
    ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC50 value of 1 nM. ATR-IN-29 shows antiproliferative activity.
    ATR-IN-29
Cat. No. Product Name / Synonyms Application Reactivity
ATM/ATR Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.